Robert Vanner, University of Toronto

Research

Breast Cancer Cancer Clonal Hematopoiesis Genomics Immunology Metastasis Breast Cancer Survival Tet2-Mutant Clonal Hematopoiesis

Latest papers

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.
Nature communications · 2025
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
The Journal of clinical investigation · 2019
A Healthy Infant Incidentally Presenting With Low SpO2: The Pitfalls of Pulse Oximetry.
Clinical pediatrics · 2018 · first author

All 5 publications

Latest funding

TET2-mutant clonal hematopoiesis as a determinant of breast cancer survival
CIHR · 2025 · Nominated PI
$25,000
TET2-mutant clonal hematopoiesis as a determinant of breast cancer survival
CIHR · 2025 · Nominated PI
$1,086,300

All 2 grants and awards

5 publications.

01

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.

Yang Y, Cathelin S, Liu ACH, Subedi A, Maher A, Hosseini M, Manikoth Ayyathan D, Vanner R, Chan SM

Nature communications2025

DOI: 10.1038/s41467-025-57614-y PMID: 40064887

02

DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.

Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U

The Journal of clinical investigation2019

DOI: 10.1172/jci121303 PMID: 30358567

03

A Healthy Infant Incidentally Presenting With Low SpO2: The Pitfalls of Pulse Oximetry.

Vanner R, Cho R, Weinstein M

Clinical pediatrics2018First author

DOI: 10.1177/0009922816681604 PMID: 27941085

04

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

Remke M, Ramaswamy V, Peacock J, Shih DJH, Koelsche C, Northcott PA, Hill N, Cavalli FMG, Kool M, Wang X

Acta Neuropathologica2013166 citationsOpen Access

DOI: 10.1007/s00401-013-1198-2 PMID: W2108862374

05

A tumorigenic MLL-homeobox network in human glioblastoma stem cells.

Gallo M, Ho J, Coutinho FJ, Vanner R, Lee L, Head R, Ling EK, Clarke ID, Dirks PB

Cancer research2013

DOI: 10.1158/0008-5472.can-12-1881 PMID: 23108137

TET2-mutant clonal hematopoiesis as a determinant of breast cancer survival

Nominated PICIHR2025PRIZE - Project Grant - PA: Prize: Early Career Investigator in Cancer

Principal investigators: Vanner, Robert J

Keywords: Breast Cancer Survival; Tet2-Mutant Clonal Hematopoiesis

$25,000

TET2-mutant clonal hematopoiesis as a determinant of breast cancer survival

Nominated PICIHR2025Project Grant

Principal investigators: Vanner, Robert J

Keywords: Breast Cancer; Cancer; Clonal Hematopoiesis; Genomics; Immunology; Metastasis

$1,086,300

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Pediatrics
Neurosurgery
Genetics and Genome Biology
Pathology & Molecular Medicine
Molecular Oncology
Department of Paediatrics
Neurology and Neurosurgery
Other

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Breast Cancer Dear Professor Vanner, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling." (2025), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "TET2-mutant clonal hematopoiesis as a determinant of breast cancer survival" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]